Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab long-term randomized withdrawal extension study in hidradenitis suppurativa
NL-OMON54433Phase 3Recruiting
- Sponsor
- Novartis
- Start
- Feb 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of secukinumab in hidradenitis suppurativa (HS), sponsored by Novartis. Started Feb 2021; status: recruiting.
02
Drugs
secukinumab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NL-OMON54433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54433.